Expert Insights into the Management of Newly Diagnosed Ph+ ALL

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.

Hagop M. Kantarjian, MD, and Bijal D. Shah, MD, MS, delve into upcoming strategies for handling Philadelphia-chromosome positive acute lymphoblastic leukemia, considering recent breakthroughs.